Showing results (271-280 of 776) with videos related to
Sort By:
Pageof 78
Lancet (London, England)|August 27, 2013
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trialAnna Caroli, Norberto Perico, Annalisa Perna, et al.Kidney International|April 5, 2003
Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual levelBorislav D Dimitrov, Annalisa Perna, Piero Ruggenenti, et al.Clinical Biochemistry|October 24, 2006
Comparison of the Innofluor certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantationSara Baldelli, Alberto Crippa, Roberta Gabrieli, et al.Fibrogenesis & Tissue Repair|May 6, 2010
The role of renin angiotensin system inhibition in kidney repairIrene M van der Meer, Paolo Cravedi, Giuseppe RemuzziBMJ Case Reports|January 26, 2020
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sicknessManuel Alfredo Podestà, Barbara Ruggiero, Giuseppe Remuzzi, et al.Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathyPaolo Cravedi, Piero Ruggenenti, Maria Chiara Sghirlanzoni, et al.Journal of Renal Care|July 1, 2010
The diabetic CKD patient--a major cardiovascular challengeIrene M van der Meer, Piero Ruggenenti, Giuseppe RemuzziClinical Journal of the American Society of Nephrology : CJASN|December 17, 2009
Enzyme replacement therapy and Fabry nephropathyDavid G Warnock, Erica Daina, Giuseppe Remuzzi, et al.Kidney International|October 14, 2011
The contribution of chronic kidney disease to the global burden of major noncommunicable diseasesWilliam G Couser, Giuseppe Remuzzi, Shanthi Mendis, et al.Plos Medicine|April 6, 2019
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trialNorberto Perico, Piero Ruggenenti, Annalisa Perna, et al.Pageof 78